Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2012 Nov 15;22(1):91–101. doi: 10.1158/1055-9965.EPI-12-0545

Figure 2.

Figure 2

Percentage of patients who received KRAS testing before EGFR Inhibitor treatment (white bars) and at any time in their clinical care (black bars) by year that EGFR inhibitor treatment was initiated, among patients who received EGFR inhibitors.